NSE: LUPIN | BSE: 500257

Strong Performer, Getting Expensive

Download real time

2199.30 -11.80 (-0.53%)

Near 52W High of ₹2244.50

1.2M NSE+BSE Volume

NSE 13 Feb, 2026 3:31 PM (IST)

100,501

Market Cap

High in industry

Beta 1Year

Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Search Inside the pdf :

Lupin Ltd.

16 Jan 2026, 12:00AM

2199.30

-0.53%

Healing and Health

Buy: Lupin Ltd.

FundsIndia

U.S. business grew ~41% YoY in Q2FY26, led by specialty & complex launches. Europe up ~27% YoY; Other Developed Markets up ~19%.

Lupin Ltd. has an average target of 2336.09 from 11 brokers.

Lupin Ltd.

25 Nov 2025

2199.30

-0.53%

LUPIN LIMITED

Buy: Lupin Ltd.

Recommendation Target

Geojit BNP Paribas

In Q2FY26, Lupin reported a consolidated revenue of Rs. 7,048cr, up 24.2% YoY, Lupin's India segment revenue rose 3.4% YoY to Rs. 2,078cr, led by an 8.8% growth in Rx business, strong chronic therapy momentum and robust volume growth,...

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

13 Nov 2025

2199.30

-0.53%

Record quarter with broad-based growth, strong U.S. momentum, and sharp margin expansion

Buy: Lupin Ltd.

Deven Choksey

Lupin remains well-positioned to sustain its strong growth trajectory, supported by a healthy specialty pipeline in the U.S., improved product mix, and operating leverage gains.

Lupin Ltd. has an average target of 2336.09 from 11 brokers.

Lupin Ltd.

11 Nov 2025

2199.30

-0.53%

Lupin Ltd

Buy: Lupin Ltd.

Recommendation Target

ICICI Direct

Niche launches in the US drive numbers; future pipeline key for sustainability Earning momentum strong till FY26; apparent slowdown in FY27 but pipeline buildup to continue- Strong growth was attributable US launches under exclusivity (gMyrbetriq, gTolvaptan and gSpiriva) and launches across regions. India was impacted due to lower tender sales in Institutional business. The company has maintained the strong EBITDA margins trajectory mainly driven by strong GPM performance. The...

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

10 Nov 2025

2199.30

-0.53%

Lupin (BUY): Massive beat on earnings; margin guidance raised for FY26

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 15%/37%/47% above estimates. Adj. forex gain PAT reported 27% above estimates.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

10 Nov 2025

2199.30

-0.53%

Lupin (LPC IN) Q2FY26 Result Update Strong beat...

Buy: Lupin Ltd.

Prabhudas Lilladhar

Lupin Ltd. has an average target of 2336.09 from 11 brokers.

Lupin Ltd.

09 Nov 2025

2199.30

-0.53%

Strong quarter, grim outlook on pipeline

Hold: Lupin Ltd.

ICICI Securities Limited

Lupin delivered a beat of 9.5%/26.3%/21.8% in revenue/EBITDA/PAT vs our estimates in Q2FY26, driven by exclusive products like Tolvaptan and Mirabegron.